Clinical Trials · NCT00686348

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

Name: Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 260
Start date: May 2008
Locations: 1 site, United States
Primary endpoint: Assess the safety & effectiveness, as measured by IGF-1 & GH levels, of Somatuline® Depot Injection when administered by a health care professional, the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

View Lanreotide compound reference